People whose virus has become resistant to approved HIV treatments or who are intolerant to them will take tipranavir with Norvir, along with other anti-HIV drugs, for an open period of time. Participants should be 13 years of age or older, have a viral load above 10,000 and a CD4 count below 100 to enroll in this program.
People who have high cholesterol levels and a viral load below 50 while taking Kaletra will either switch to Reyataz or continue taking Kaletra. The study will last 12 months. Study participants will be reimbursed $25 for each visit.
People whose viral load has risen to over 1,000 while taking an NNRTI as part of their first HAART regimen will switch to either Kaletra, or to Reyataz / Norvir. Everyone will also take Viread and either Videx EC or Zerit XR. The study will last for 22 months. Study participants will be reimbursed $25 for each visit.
People who have become resistant to an NNRTI and who have a CD4 count over 200 and a viral load over 2000 will take one of four doses of W695634G alone, or take placebo pills, for 7 days. Those who complete the study will be reimbursed $590.
For the above trials, contact Dr. Douglas Mendez at 212-924-3934 ext. 126 or Dr. Yuriy Akulov at 212-924-3934 ext. 124.
This trial is studying whether people on their first HAART regimen who take their drugs two or more times a day can switch to a once-daily regimen. People in the trial either remain on their current medications, or switch to Zerit XR, Epivir and Sustiva (ZEST) taken once daily.
ACRIA is collaborating with researchers at Indiana University and with the Association for Nurses in AIDS Care (ANAC) to conduct a study of issues facing nursing professionals who provide care to people living with HIV. The study is being conducted via the Internet and participation is anonymous. Nursing professionals can participate by visiting our website, www.acria.org or http://webdb.iu.edu/Hperweb/icts/hiv_survey/index.html.
This article was provided by AIDS Community Research Initiative of America. It is a part of the publication ACRIA Update. Visit ACRIA's website to find out more about their activities, publications and services.